Tamoxifen Update

Sugerman, Deborah Tolmach
August 2013
JAMA: Journal of the American Medical Association;8/28/2013, Vol. 310 Issue 8, p866
Academic Journal
The article provides information on the drug Tamoxifen. Tamoxifen is a drug that blocks the effects of the hormone estrogen. It is used as a treatment for breast cancer patients whose tumors have estrogen receptors, called ER positive. It is often used after surgery or radiation therapy and also used for cancer prevention in women. Its side effects include blood clots, stroke and cataracts.


Related Articles

  • Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. Larsen, Sarah L.; Yde, Christina W.; Laenkholm, Anne-Vibeke; Rasmussen, Birgitte B.; Duun-Henriksen, Anne Katrine; Bak, Martin; Lykkesfeldt, Anne E.; Kirkegaard, Tove // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Resistance to antiestrogen therapy is a major clinical challenge in the treatment of estrogen receptor α (ER)-positive breast cancer. The aim of the study was to explore the growth promoting pathways of antiestrogen resistant breast cancer cells to identify biomarkers and novel...

  • Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Mojarrad, Majid; Momeny, Majid; Mansuri, Fatemeh; Abdolazimi, Yassan; Tabrizi, Mina Hajifaraj; Ghaffari, Seyed Hamidollah; Tavangar, Seyed Mohammad; Modarressi, Mohammad Hussein // Medical Oncology;Jun2010, Vol. 27 Issue 2, p474 

    Tamoxifen is the most common antiestrogen used in the treatment of estrogen-positive breast cancer but its adverse effects and also resistance to this drug are serious challenges in the treatment of breast cancer. Characterization of mechanisms responsible for these adverse effects can lead to...

  • The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. Yan Ni Loh; Hedditch, Ellen L.; Baker, Laura A.; Jary, Eve; Ward, Robyn L.; Ford, Caroline E. // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Acquired resistance to Tamoxifen remains a critical problem in breast cancer patient treatment, yet the underlying causes of resistance have not been fully elucidated. Abberations in the Wnt signalling pathway have been linked to many human cancers, including breast cancer, and...

  • Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells. Woo, Yu Mi; Shin, Yubin; Lee, Eun Ji; Lee, Sunyoung; Jeong, Seung Hun; Kong, Hyun Kyung; Park, Eun Young; Kim, Hyoung Kyu; Han, Jin; Chang, Minsun; Park, Jong-Hoon // PLoS ONE;7/9/2015, Vol. 10 Issue 7, p1 

    Tamoxifen resistance is often observed in the majority of estrogen receptor–positive breast cancers and it remains as a serious clinical problem in breast cancer management. Increased aerobic glycolysis has been proposed as one of the mechanisms for acquired resistance to chemotherapeutic...

  • Intraabdominal desmoid tumour presenting with perforation. Jalini, L; Hemming, D.; Bhattacharya, V. // Surgeon (Edinburgh University Press);Apr2006, Vol. 4 Issue 2, p114 

    We present a rare case of a desmoid tumour presenting with perforation of the small bowel, Although desmoid is classified pathologically as a benign tumour, its infiltrative nature leads to a locally aggressive mass, which can invade surrounding structures and organs making surgical resection...

  • Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha. Chakraborty, Sandipan; Biswas, Pradip // Journal of Molecular Modeling;Aug2014, Vol. 20 Issue 8, p1 

    Tamoxifen-an anti-estrogenic ligand in breast tissues used as a first-line treatment in estrogen receptor (ER)-positive breast cancers-is associated with the development of resistance followed by resumption of tumor growth in about 30 % of cases. Whether tamoxifen assists in proliferation in...

  • XIAP inhibitor and antiestrogen embelin abrogates metastasis and augments apoptosis in estrogen receptor positive human breast adenocarcinoma cell line MCF-7. Sumalatha, K.; Abiramasundari, G.; Chetan, G.; Divya, T.; Sudhandiran, G.; Sreepriya, M. // Molecular Biology Reports;Feb2014, Vol. 41 Issue 2, p935 

    Tamoxifen therapy for the treatment of hormone responsive breast cancer has limitations due to acquired resistance in the case of recurrences. Embelin, a known inhibitor of X-linked inhibitor of apoptosis protein (XIAP) was also reported to exhibit strong antiestrogenic effects in animal models....

  • MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Rao, X; Di Leva, G; Li, M; Fang, F; Devlin, C; Hartman-Frey, C; Burow, M E; Ivan, M; Croce, C M; Nephew, K P // Oncogene;3/3/2011, Vol. 30 Issue 9, p1082 

    Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies. However, after prolonged fulvestrant therapy, acquired resistance eventually occurs in...

  • Fulvestrant: A Viewpoint by Roger W. Blamey. Blamey, R.W. // Drugs;Apr2001, Vol. 61 Issue 6, p814 

    Presents information on fulvestrant, an anti-estrogen antagonist, indicated for treating breast cancer. Comparison between fulvestrant and tamoxifen as estrogen receptors; Limitations of the effect of the fulvestrant.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics